Skorpios Trust

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed October 23, 2024), Skorpios Trust reported 2 stock positions worth $109.6 million. Its top holding was Stoke Therapeutics (STOK) at 99.8% of the portfolio, followed by SS SPDR S&P Biotech ETF (XBI, 0.2%). Compared with Q2 2024, it reduced 1. The biggest sale was Stoke Therapeutics (STOK, shares −18%).

Most Recent 13F
Q3 2025
Location
LIMASSOL, G4
CIK
0001869333
Portfolio Value
$109.6M (Q3 2024)
SEC Filing
0001123292-24-000318 ↗ filed Oct 23, 2024

Holdings Value

0$50.0M$100.0M$150.0M$200.0M Q1 2024: $195.1M Q1 2024 Q2 2024: $146.7M Q2 2024 Q3 2024: $109.6M $109.6M Q3 2024 Q4 2024: $76.3M Q4 2024 Q1 2025: $46.1M Q1 2025 Q2 2025: $37.1M Q2 2025 Q3 2025: $53.2M Q3 2025

Holdings 2 stocks · $109.6M
STOK Stoke Therapeutics Inc. 99.85% 8,906,181 $109.5M Reduce -17.9%
XBI SS SPDR S&P Biotech ETF 0.15% 1,686 $167K No change

Portfolio Sells Q2 2024 → Q3 2024
STOK Stoke Therapeutics Inc. Reduce -17.9% 99.85% −0.05

Portfolio Buys Q2 2024 → Q3 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 2$53.2MSTOK, XBI
Q2 2025 2$37.1MSTOK, XBI
Q1 2025 2$46.1MSTOK, XBI
Q4 2024 2$76.3MSTOK, XBI
Q3 2024 2$109.6MSTOK, XBI
Q2 2024 2$146.7MSTOK, XBI
Q1 2024 2$195.1MSTOK, XBI